2020
Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials
Madhavan MV, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok NJ, Burton JR, Crowley A, Francese DP, Gupta A, Der Nigoghossian C, Chatterjee S, Palmerini T, Benedetto U, You S, Ohman M, Kastrati A, Steg PG, Gibson C, Angiolillo DJ, Krumholz HM, Stone GW. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardioangiologica 2020 DOI: 10.23736/s0026-4725.20.05353-0.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeHumansNetwork Meta-AnalysisPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicAntiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials.
Madhavan M, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok N, Burton J, Crowley A, Francese D, Gupta A, DER Nigoghossian C, Chatterjee S, Palmerini T, Benedetto U, You S, Ohman E, Kastrati A, Steg P, Gibson C, Angiolillo D, Krumholz H, Stone G. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardioangiologica 2020, 69: 398-407. PMID: 33258563, DOI: 10.23736/s2724-5683.20.05353-0.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeHumansNetwork Meta-AnalysisPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicConceptsAcute coronary syndromeNetwork meta-analysisIncidence rate ratiosReceptor inhibitorsRandom-effects methodMeta-analysisCoronary syndromeMonths of follow-up timePatients of advanced ageControlled trialsBackground of aspirinEfficacy of prasugrelST-elevation myocardial infarctionCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsFollow-up timeFrequentist network meta-analysisManagement of patientsRegister of Controlled TrialsShort-term outcomesLong-term outcomesCochrane Central RegisterRandomized controlled trialsHemorrhagic outcomesAntiplatelet strategiesSulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, Francese DP, Gibson CM, Piazza G, Goldhaber SZ, Eikelboom JW, Krumholz HM, Stone GW. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars In Thrombosis And Hemostasis 2020, 46: 908-918. PMID: 33086402, DOI: 10.1055/s-0040-1716874.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsGlycosaminoglycansHemorrhageHumansRandomized Controlled Trials as TopicRisk FactorsThrombosisConceptsDeep vein thrombosisUse of sulodexideCause mortalityCardiovascular mortalityReduced oddsPulmonary embolismOdds ratioOdds of VTESafety of sulodexideCardiovascular risk factorsCochrane Central RegisterPeripheral arterial diseaseHistory of MIThrombotic cardiovascular diseasesRandom-effects modelCardiovascular efficacyOral glycosaminoglycansCardiovascular outcomesHemorrhagic eventsCentral RegisterVein thrombosisControlled TrialsArterial diseaseRandomized trialsRisk factors
2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology
Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y, Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, Kastrati A, Schüpke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, Valgimigli M, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis And Haemostasis 2019, 120: 348-362. PMID: 31820428, PMCID: PMC7040882, DOI: 10.1055/s-0039-1700872.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAnticoagulantsData Interpretation, StatisticalDatabases, FactualDrug Administration ScheduleHeparinHirudinsHumansMedical InformaticsMyocardial InfarctionOutcome Assessment, Health CarePeptide FragmentsPercutaneous Coronary InterventionRandomized Controlled Trials as TopicRecombinant ProteinsRiskTreatment OutcomeConceptsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionIndividual patient databaseProlonged bivalirudin infusionSegment elevation MIIndividual patient dataPatient-level dataDifferent relative risksConsensus-based definitionBivalirudin infusionPeriprocedural anticoagulationAnticoagulation regimenCoronary interventionElevation MIFemoral accessRandomized trialsPatient groupOutcome definitionsRelative riskPrespecified criteriaBivalirudinTrial publicationsST segmentPatient database
2015
The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial.
Madhavan MV, Généreux P, Palmerini T, Caixeta A, Xu K, McAndrew TC, Francese DP, Kirtane AJ, Mehran R, Stone GW. The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial. Journal Of Invasive Cardiology 2015, 27: 203-11. PMID: 25840404.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleHumansMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisPercutaneous Coronary InterventionPostoperative HemorrhageProportional Hazards ModelsProspective StudiesRandomized Controlled Trials as TopicRisk FactorsConceptsNon-ST segment elevation acute coronary syndromesPercutaneous coronary interventionCoronary artery diseaseExtent of CADMajor bleeding ratesSYNTAX scoreACUITY trialMajor bleedingCoronary interventionArtery diseaseBleeding rateSegment elevation acute coronary syndromesSeverity of CADElevation acute coronary syndromeSevere coronary artery diseaseAdverse ischemic eventsMajor bleeding eventsAcute coronary syndromeCommon risk factorsRecurrent adverse eventsBleeding eventsPCI cohortSS tertilesCoronary syndromeHemorrhagic events